— Know what they know.
Not Investment Advice
Also trades as: AUROPHARMA.NS (NSE) · $vol 28M

AUROPHARMA.BO BSE

Aurobindo Pharma Limited
1W: +2.4% 1M: +11.4% 3M: +34.6% YTD: +37.7% 1Y: +36.7% 3Y: +232.9% 5Y: +86.7%
₹1,458.60 ($15.24)
-87.85 (-5.68%)
 
Weekly Expected Move ±3.4%
₹1411 ₹1463 ₹1515 ₹1568 ₹1620
BSE · Healthcare · Drug Manufacturers - Specialty & Generic · Alpha Radar Buy · Power 60 · ₹850.7B mcap · 279M float · 0.015% daily turnover
Smart Money Score
Watch 25
Insider
Congress
ETF Holdings
Key Statistics
Market Cap₹850.7B ($8.9B)
52W Range994.35-1524.6
Volume131,488
Avg Volume41,090
Beta0.05
Dividend₹4.00
Analyst Ratings
No analyst coverage
Company Info
CEOMakkapati Satakarni
Employees26,015
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2000-01-03
Galaxy, Plot No. 1
Hyderabad 500032
IN
91 40 6672 5000
About Aurobindo Pharma Limited

Aurobindo Pharma Limited engages in manufacturing of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, and internationally. It offers formulation in form of orals, injectables and over-the-counter drugs; and active pharmaceutical ingredients (API) for biosimilars, dermatology, respiratory, vaccines, and peptides, as well as oncology, hormones, and sterile products. The company also provides antiretroviral drugs for the people and children living with HIV; and AuroZymes, a biocatalysts product for use in the pharmaceutical and chemical industries. In addition, it offers AuroSource, a contract services that cover the clinical stage through to manufacturing and management of the entire drug lifecycle in the API space for penicillin's, cephalosporins, and non beta lactams. The company was incorporated in 1986 and is headquartered in Hyderabad, India.

Latest News
No recent news

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms